$10.9 M

PSTV Mkt cap, 23-Sept-2020
PLUS THERAPEUTICS Net income (Q2, 2020)-1.8 M
PLUS THERAPEUTICS EBIT (Q2, 2020)-2.4 M
PLUS THERAPEUTICS Cash, 30-Jun-20209.3 M
PLUS THERAPEUTICS EV8.3 M

PLUS THERAPEUTICS Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

8.0m8.7m7.1m5.0m4.8m4.7m2.7m3.7m

Revenue growth, %

(30%)(2%)(4%)

Cost of goods sold

3.8m4.0m3.4m2.9m3.2m2.7m1.1m

Gross profit

4.1m4.7m3.7m2.0m1.7m1.9m2.5m

Gross profit Margin, %

52%54%52%41%34%42%69%

Sales and marketing expense

13.6m9.5m9.0m6.4m2.7m3.6m3.6m2.0m468.0k

R&D expense

10.9m13.6m17.1m15.1m19.0m16.2m11.7m8.6m5.4m

General and administrative expense

14.7m15.7m16.0m16.0m9.8m8.6m7.6m6.3m4.8m

Operating expense total

33.6m33.1m42.1m37.5m31.4m28.4m20.8m15.2m10.7m

EBIT

(29.4m)(28.4m)(30.7m)(32.4m)(15.3m)(19.7m)(20.7m)(12.7m)(3.7m)

EBIT margin, %

(368%)(326%)(431%)(655%)(316%)(423%)(769%)(346%)

Interest expense

2.8m3.4m3.4m4.4m3.4m2.6m2.0m64.0k

Interest income

9.0k4.0k4.0k6.0k9.0k19.0k33.0k43.0k55.0k

Investment income

(209.0k)(165.0k)

Pre tax profit

(21.9m)(12.2m)(3.4m)

Income tax expense

Net Income

(32.5m)(32.3m)(26.2m)(37.4m)(18.7m)(22.0m)(22.7m)(12.6m)(10.9m)

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

2.4m2.1m1.5m1.9m1.3m1.4m1.4m1.6m1.0m935.0k518.0k902.0k1.6m766.0k1.3m1.1m731.0k591.0k969.0k467.0k731.0k660.0k858.0k703.0k

Cost of goods sold

1.1m942.0k853.0k1.0m703.0k756.0k608.0k931.0k421.0k766.0k337.0k598.0k1.3m502.0k567.0k585.0k618.0k

Gross profit

1.3m1.2m628.0k915.0k611.0k636.0k800.0k685.0k610.0k169.0k181.0k304.0k318.0k264.0k766.0k541.0k113.0k

Gross profit Margin, %

54%56%42%47%46%46%57%42%59%18%35%34%20%34%57%48%15%

Sales and marketing expense

3.7m3.6m2.4m2.6m2.5m2.3m2.4m1.8m1.9m1.9m1.5m839.0k654.0k566.0k1.0m889.0k818.0k939.0k1.3m840.0k678.0k525.0k453.0k428.0k97.0k94.0k110.0k105.0k

R&D expense

3.1m2.8m2.8m3.2m3.6m3.7m4.2m4.1m4.3m4.7m3.1m4.0m6.0m4.4m4.1m5.2m4.0m3.3m3.0m3.0m2.5m2.0m1.9m1.8m1.3m921.0k941.0k327.0k

General and administrative expense

4.1m3.5m3.9m3.8m3.8m3.8m4.0m4.3m4.3m4.6m4.2m2.5m2.8m2.4m2.3m2.3m2.0m2.1m2.1m1.8m2.2m1.5m1.5m1.5m875.0k1.1m1.5m1.3m

Operating expense total

5.7m9.0m9.0m7.9m10.9m7.4m7.2m9.1m10.2m10.9m8.1m21.3m(5.5m)(1.7m)5.9m6.8m4.9m7.0m5.8m4.3m4.5m3.0m1.7m3.8m2.3m2.1m2.6m1.8m

EBIT

(4.4m)(7.8m)(8.4m)(7.0m)(10.3m)(6.7m)(6.4m)(8.5m)(9.5m)(10.7m)(7.9m)(21.0m)5.8m2.0m(5.1m)(6.2m)(4.8m)(7.1m)(5.6m)(4.3m)(4.4m)(3.0m)(1.5m)(3.0m)(2.0m)2.7m(2.4m)(2.4m)

EBIT margin, %

(181%)(367%)(565%)(357%)(786%)(484%)(452%)(524%)(926%)(1143%)(1523%)(2328%)359%261%(382%)(553%)(656%)(1206%)(576%)(930%)(595%)(457%)(174%)(427%)

Interest expense

696.0k489.0k865.0k860.0k857.0k709.0k652.0k1.1m941.0k1.1m1.3m1.1m936.0k669.0k657.0k645.0k645.0k591.0k538.0k474.0k423.0k444.0k512.0k515.0k597.0k366.0k349.0k252.0k

Interest income

1.0k3.0k2.0k1.0k1.0k1.0k2.0k1.0k1.0k1.0k3.0k3.0k2.0k2.0k4.0k11.0k7.0k5.0k14.0k5.0k11.0k7.0k7.0k6.0k36.0k9.0k

Investment income

(56.0k)(51.0k)(50.0k)(37.0k)(42.0k)(48.0k)

Net Income

(5.1m)(8.3m)(9.3m)(7.9m)(11.2m)(7.7m)(3.2m)(5.3m)(10.4m)(11.8m)(9.4m)(22.0m)4.5m1.5m(5.3m)(6.4m)(5.4m)(7.5m)(6.0m)(4.8m)(4.4m)(3.7m)(2.3m)(3.1m)(9.1m)526.0k(1.1m)(1.8m)

PLUS THERAPEUTICS Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

33.2m40.8m34.4m25.8m17.6m16.4m13.6m10.2m12.8m12.8m7.8m13.2m23.8m19.0m9.4m20.0m14.9m6.3m9.0m4.8m5.9m3.1m6.8m3.9m4.5m16.8m16.1m9.3m

Accounts Receivable

2.5m2.0m1.4m2.0m1.5m3.0m2.9m2.6m3.6m2.0m532.0k704.0k750.0k1.1m829.0k911.0k918.0k873.0k807.0k230.0k769.0k399.0k440.0k455.0k80.0k4.8m978.0k951.0k

Prepaid Expenses

849.0k702.0k1.1m1.1m1.1m1.2m1.2m1.1m1.4m1.3m1.2m1.3m986.0k1.3m1.9m1.3m1.3m500.0k1.1m892.0k837.0k837.0k654.0k1.1m503.0k502.0k

Inventories

3.9m4.2m3.4m3.1m3.4m3.6m4.0m4.1m4.2m4.5m5.0m4.6m4.1m4.6m4.5m4.5m3.9m4.1m4.2m3.5m3.2m3.0m2.8m3.0m107.0k107.0k107.0k107.0k

Current Assets

40.4m47.6m40.3m32.0m23.6m24.2m21.7m18.1m22.1m20.5m14.6m19.9m29.7m26.0m16.5m26.8m21.0m12.1m15.6m9.8m10.7m7.4m10.8m8.5m5.3m22.3m17.7m10.8m

PP&E

1.9m1.8m2.4m2.3m2.2m2.0m2.0m1.6m1.2m1.3m1.6m1.8m1.9m1.7m1.5m1.4m1.3m3.6m3.4m3.3m2.9m2.8m2.6m2.6m2.3m2.2m2.1m2.0m

Goodwill

3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m3.9m372.0k372.0k372.0k372.0k

Total Assets

48.8m55.6m49.1m40.5m32.0m33.4m39.8m35.2m39.4m38.3m32.3m37.0m46.5m42.4m32.9m42.7m36.8m29.8m32.5m26.4m26.6m22.7m25.5m24.6m8.9m25.7m21.0m13.9m

Accounts Payable

6.9m6.4m6.0m5.1m5.6m6.0m6.3m5.5m6.4m6.5m5.7m5.6m7.0m6.3m6.7m6.6m5.6m6.2m6.5m4.9m4.2m3.8m3.6m3.2m3.0m3.3m3.7m3.6m

Short-term debt

8.8m69.0k4.9m7.3m9.8m9.8m21.0k1.2m5.2m7.3m5.5m10.0m26.0k1.4m1.7m3.5m5.3m6.7m6.7m13.5m13.7m13.8m14.0m14.4m10.8m10.9m11.2m6.0m

Current Liabilities

15.6m6.4m11.0m12.4m15.4m16.7m7.8m12.6m14.8m16.7m14.5m18.7m9.2m9.5m9.7m10.1m10.9m12.9m13.2m18.4m17.9m17.6m17.7m18.3m13.9m14.4m15.0m9.8m

Long-term debt

9.3m24.2m19.7m17.4m15.2m10.6m25.7m24.8m21.3m19.5m20.3m15.7m16.2m15.0m15.2m13.7m12.1m9.4m7.8m84.0k54.0k38.0k4.0k589.0k

Total Debt

18.1m24.3m24.6m24.8m24.9m20.4m25.7m26.0m26.6m26.8m25.8m25.7m16.2m16.4m16.9m17.2m17.4m16.1m14.5m13.5m13.7m13.8m14.0m14.5m10.9m11.0m11.2m6.6m

Total Liabilities

38.6m43.6m42.3m40.0m41.7m31.0m38.5m38.4m37.0m37.1m35.6m60.2m44.3m37.4m25.2m24.0m23.2m22.4m21.2m18.6m18.2m17.9m19.4m20.8m15.2m25.6m20.9m10.6m

Common Stock

52.0k55.0k58.0k59.0k59.0k67.0k67.0k67.0k75.0k79.0k83.0k114.0k151.0k159.0k13.0k20.0k20.0k24.0k33.0k35.0k62.0k62.0k67.0k22.0k443.1k3.0k4.0k4.0k

Preferred Stock

Additional Paid-in Capital

237.3m247.4m258.6m260.1m261.1m284.8m286.8m287.8m313.4m323.8m328.7m336.2m356.9m358.0m369.3m386.8m387.1m392.7m402.7m404.0m413.5m413.3m417.0m420.3m420.4m426.3m426.4m431.5m

Retained Earnings

(227.2m)(235.5m)(251.8m)(259.7m)(270.9m)(282.4m)(285.6m)(290.9m)(311.3m)(323.1m)(332.5m)(360.2m)(355.8m)(354.3m)(362.4m)(368.8m)(374.1m)(386.6m)(392.7m)(397.5m)(406.2m)(409.8m)(412.1m)(417.5m)(426.7m)(426.2m)(426.4m)(428.2m)

Total Equity

10.1m11.9m6.9m548.0k(9.7m)2.4m1.3m(3.2m)2.4m1.2m(3.3m)(23.2m)2.3m5.0m7.7m18.7m13.7m7.4m11.2m7.8m8.5m4.8m6.1m3.9m(6.3m)160.0k85.0k3.3m

Financial Leverage

4.8 x4.7 x7.2 x73.9 x-3.3 x14.1 x31.5 x-11 x16.4 x32.1 x-9.8 x-1.6 x20.6 x8.5 x4.3 x2.3 x2.7 x4 x2.9 x3.4 x3.1 x4.8 x4.2 x6.4 x-1.4 x160.7 x246.7 x4.2 x

PLUS THERAPEUTICS Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(17.2m)(25.5m)(9.3m)(17.2m)(28.5m)(7.7m)(10.9m)(16.1m)(10.4m)(22.2m)(31.6m)(22.0m)(17.5m)(16.0m)(5.3m)(11.7m)(17.1m)(7.5m)(13.6m)(18.4m)(4.4m)(8.1m)(10.4m)(3.1m)(12.3m)(11.8m)(1.1m)(2.9m)

Depreciation and Amortization

400.0k621.0k220.0k453.0k712.0k200.0k660.0k1.2m160.0k344.0k525.0k213.0k510.0k761.0k291.0k574.0k794.0k442.0k1.1m1.6m497.0k975.0k1.5m443.0k617.0k778.0k94.0k188.0k

Accounts Receivable

623.0k168.0k859.0k258.0k698.0k868.0k862.0k361.0k49.0k1.4m2.5m546.0k544.0k131.0k155.0k66.0k91.0k335.0k409.0k991.0k(747.0k)(274.0k)(316.0k)(212.0k)(28.0k)(4.9m)191.0k218.0k

Inventories

513.0k775.0k(56.0k)210.0k(93.0k)(477.0k)(816.0k)(975.0k)(551.0k)(526.0k)(1.2m)100.0k730.0k(10.0k)(206.0k)(380.0k)190.0k7.0k159.0k457.0k141.0k371.0k615.0k16.0k235.0k274.0k

Accounts Payable

92.0k(396.0k)(83.0k)(268.0k)254.0k(523.0k)(279.0k)(1.1m)351.0k124.0k(666.0k)138.0k1.1m870.0k176.0k(431.0k)(1.0m)(484.0k)(194.0k)(1.7m)(556.0k)(1.2m)(1.3m)(405.0k)(94.0k)(95.0k)410.0k371.0k

Cash From Operating Activities

(19.5m)(27.4m)(7.7m)(16.0m)(23.9m)(9.3m)(17.0m)(25.1m)(9.0m)(18.1m)(25.4m)(5.0m)(9.8m)(15.9m)(5.1m)(10.7m)(15.4m)(4.8m)(9.9m)(13.9m)(4.1m)(6.8m)(9.5m)(3.3m)(4.8m)(6.9m)(1.5m)(2.9m)

Purchases of PP&E

(433.0k)(458.0k)(25.0k)(886.0k)(1.1m)(81.0k)(432.0k)(536.0k)(287.0k)(467.0k)(792.0k)(187.0k)(497.0k)(544.0k)(69.0k)(105.0k)(110.0k)(5.0k)(95.0k)(271.0k)(53.0k)(78.0k)(128.0k)(6.0k)(6.0k)(8.0k)(11.0k)(23.0k)

Cash From Investing Activities

(433.0k)(458.0k)(25.0k)(886.0k)(1.1m)(281.0k)(827.0k)3.9m(642.0k)(1.1m)(1.4m)(187.0k)(510.0k)(557.0k)(69.0k)(105.0k)(110.0k)(1.2m)(1.4m)(1.5m)(53.0k)(78.0k)(128.0k)(6.0k)2.8m2.8m(11.0k)(423.0k)

Long-term Borrowings

(2.2m)(4.5m)(71.0k)(140.0k)(210.0k)(2.5m)(22.3m)(22.3m)(1.3m)(25.0m)(25.0m)(1.8m)(3.5m)(4.7m)(28.0k)(642.0k)(642.0k)(18.0k)(5.3m)

Dividends Paid

(72.0k)(75.0k)(75.0k)

Cash From Financing Activities

526.0k16.0m5.2m5.7m5.7m332.0k5.8m5.8m6.9m16.5m19.2m3.8m19.5m20.9m62.0k16.4m15.9m(335.0k)7.7m7.7m(150.0k)(200.0k)6.2m1.9m1.3m15.7m(18.0k)(5.0m)

Net Change in Cash

(19.4m)(11.9m)(2.5m)(11.2m)(19.3m)(9.3m)(12.1m)(15.5m)(2.7m)(2.7m)(7.7m)(1.4m)9.2m4.3m(5.0m)5.7m586.0k(6.3m)(3.5m)(7.8m)(4.3m)(7.1m)(3.4m)(1.4m)(731.0k)11.6m(1.5m)(8.3m)

Interest Paid

989.0k1.5m625.0k1.3m1.9m520.0k1.2m1.6m659.0k1.3m2.0m612.0k1.2m1.6m400.0k805.0k1.2m384.0k740.0k1.1m311.0k649.0k990.0k347.0k826.0k1.1m227.0k372.0k

PLUS THERAPEUTICS Ratios

USDQ2, 2011

Financial Leverage

4.8 x

PLUS THERAPEUTICS Employee Rating

2.919 votes
Culture & Values
3.4
Work/Life Balance
3.1
Senior Management
2.4
Salary & Benefits
2.8
Career Opportunities
2.9
Source